Technical Analysis for PRLD - Prelude Therapeutics Incorporated

Grade Last Price % Change Price Change
grade D 30.4 2.63% 0.78
PRLD closed up 2.63 percent on Friday, October 23, 2020, on 51 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical PRLD trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Hot IPO Pullback Bullish Swing Setup 2.63%
Spinning Top Other 2.63%
Multiple of Ten Bearish Other 2.63%
Outside Day Range Expansion 2.63%
Hot IPO Pullback Bullish Swing Setup 5.52%
Narrow Range Bar Range Contraction 5.52%
NR7 Range Contraction 5.52%
Older End-of-Day Gignals for PRLD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Biopharmaceutical Solid Tumors Cancers Tyrosine Kinase Receptors Protein Kinase Inhibitors Small Molecule Therapies Phosphoinositide 3 Kinase Inhibitor Glioblastoma Multiforme Blastoma

Is PRLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 50.19
52 Week Low 24.0
Average Volume 241,855
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 34.50
10-Day Moving Average 33.37
Average True Range 4.61
ADX 0.0
+DI 23.48
-DI 17.95
Chandelier Exit (Long, 3 ATRs ) 36.36
Chandelier Exit (Short, 3 ATRs ) 37.83
Upper Bollinger Band 46.17
Lower Bollinger Band 22.84
Percent B (%b) 0.32
BandWidth 67.61
MACD Line -2.18
MACD Signal Line -1.24
MACD Histogram -0.9428
Fundamentals Value
Market Cap 990.83 Million
Num Shares 32.6 Million
EPS
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.39
Resistance 3 (R3) 33.49 32.61 32.89
Resistance 2 (R2) 32.61 31.85 32.55 32.72
Resistance 1 (R1) 31.50 31.38 32.06 31.40 32.56
Pivot Point 30.62 30.62 30.89 30.56 30.62
Support 1 (S1) 29.51 29.86 30.07 29.41 28.24
Support 2 (S2) 28.63 29.39 28.57 28.08
Support 3 (S3) 27.52 28.63 27.91
Support 4 (S4) 27.42